• Follow us on Twitter

Follow us on Twitter:

The RTCure project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement no 777357. This joint undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA.

The communication reflects the author's view; neither IMI nor the European Union or EFPIA  are responsible for any use that may be made of the information contained herein.

Objectives

The aim of the project management WP is to ensure a proper functioning of the project in order to achieve the objectives, to complete the milestones in time, to secure the deliverables and to make sure that the consortium’s contractual duties are carried out. This includes operational and scientific support to partners in the consortium in order to facilitate collaborations. WP1 will also establish an effective dissemination of project results among partners, scientific community, health policy stakeholders and patients.

 

The specific objectives of WP 1 are detailed below:

  1. Implement a project management structure that ensures that RTCure achieves its objectives, milestones and deliverables on time.

  2. Give operational and scientific support to partners in the consortium to ensure that the project is appropriately implemented and fulfils its entire obligation towards the IMI JU by strictly adhering to IMI2 regulations.

  3. Ensure effective communication and work dynamics between partners and WPs to help drive the consortium as a team towards successful project completion.

  4. Establish an effective dissemination of project results among partners, scientific community, health policy stakeholders and patients.

  5. Set up and implement a roadmap to ensure the sustainability of results beyond the time frame of the project.

Partners

  • KI (lead)

  • LUMC

  • Janssen (lead)

  • UCB

  • GSK 

  • Sanofi

  • BMS

  • PFIZER

WP1 - Management, coordination,dissemination and sustainability